Global Acute Pharyngitis Drivers 2025, Forecast To 2034
26 Mar, 2025
What Is The Current and Historic Market Size Analysis Of The Acute Pharyngitis Market?
The acute pharyngitis market has seen considerable growth due to a variety of factors.
• The market size for acute pharyngitis has experienced robust growth in recent times. The expansion is anticipated to rise from $2.67 billion in 2024 to $2.90 billion in 2025, with a compound annual growth rate (CAGR) of 8.5%.
Factors contributing to the growth during the historical period include an uptick in viral and bacterial infection cases, enhanced healthcare awareness, progress in diagnostic technologies, a surge in pediatric cases, and an escalation in environmental pollutants and allergens.
What Are The Predictions for The Acute Pharyngitis Market Size In The Coming Years?
The acute pharyngitis market is expected to maintain its strong growth trajectory in upcoming years.
• The market for acute pharyngitis is predicted to experience swift expansion in the coming years, reaching a value of $3.98 billion in 2029 with an impressive CAGR of 10.5%.
The forthcoming period of growth can be ascribed to various factors – the escalating occurrence of influenza and streptococcal infections, an increased dedication to personalized healthcare, a rising trend of quick diagnostic tests, enhancements in healthcare systems, as well as augmented access to healthcare services in developing economies. Key trends to watch for during this growth period include a shift towards over-the-counter treatment options, an uptick in the utilization of combination therapies, an expansion in telemedicine for diagnosing pharyngitis, an increased interest in natural and alternative treatments, as well as a growing predilection for self-administered and home-based treatments.
Which Drivers Are Accelerating Growth In The Acute Pharyngitis Market?
The growing frequency of influenza is projected to spur the expansion of the acute pharyngitis market in the future. Influenza is usually a result of an infection with influenza viruses which disperse through respiratory droplets due to coughs, sneezes, or contact with infected surfaces. Seasonal changes, insufficient vaccination rates, increased movement of people, virus mutations, and impaired immunity in certain groups are some reasons for increased influenza cases. Assisting influenza patients by easing throat inflammation and discomfort, decreasing difficulty in swallowing, averting secondary bacterial infections, and aiding overall recuperation, acute pharyngitis treatments can boost the human body's capacity to combat influenza effectively, when used alongside antiviral medications, sufficient hydration, and rest. For example, the US's Centers for Disease Control and Prevention reported that as of February 2025, the percentage of clinical lab tests testing positive for influenza rose to 31.6%, an increase from 29.4% the week before and 18.6% at the beginning of the year. Therefore, the escalating number of influenza cases is propelling the growth of the acute pharyngitis market.
What Are The Core Segments Of The Global Acute Pharyngitis Market?
The acute pharyngitis market covered in this report is segmented –
1) By Treatment: Antibiotics, Antivirals, Over-the-Counter (OTC) Medications, Corticosteroids And Anti-inflammatory Drugs, Alternative Remedies
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By End-User: Hospitals, Homecare, Speciality Centres, Other End Users
Subsegments:
1) By Antibiotics: Penicillins, Cephalosporins, Macrolides
2) By Antivirals: Neuraminidase Inhibitors, Nucleoside Analogs
3) By Over-the-Counter (OTC) Medications: Analgesics, Throat Lozenges, Cough Syrups
4) By Corticosteroids And Anti-inflammatory Drugs: Glucocorticoids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5) By Alternative Remedies: Herbal Teas, Honey-Based Solutions, Saltwater Gargles
Which Emerging Trends Are Reshaping The Acute Pharyngitis Market Size?
Key players in the acute pharyngitis market are investing in the development of antibiotic drugs to effectively fight bacterial infections and minimize antibiotic resistance. These antibiotics are essential for dealing with acute pharyngitis triggered by bacterial infections, like streptococcus pyogenes, as they eradicate the bacteria, alleviate symptoms, and stop potential complications such as rheumatic fever. To illustrate, Alembic Pharmaceuticals Limited, a pharmaceutical enterprise from India, was granted approval for Abbreviated New Drug Application (ANDA) by the US-based government agency, Food & Drug Administration (USFDA), for their Clarithromycin tablets USP, 250 mg and 500 mg in February 2022. This particular type of macrolide antibiotic is utilized to handle a range of mild to severe bacterial infections, including tonsillitis or pharyngitis, community-acquired pneumonia, and chronic bronchitis. The approval signifies the significance of potent antimicrobial therapies in the control of acute pharyngitis and corresponding bacterial infections.
Who Are the Key Players In The Acute Pharyngitis Market?
Major companies operating in the acute pharyngitis market are:
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Merck & Co. Inc.
• Sanofi S.A.
• Bristol-Myers Squibb
• AstraZeneca plc
• Novartis AG
• Glaxo Smithkline Pharmaceuticals Ltd
• F. Hoffmann-La Roche AG
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sandoz Group AG
• Bitop AG
• Hikma Pharmaceuticals
• Lupin Limited
• Alkem Laboratories Ltd.
• MEDICE Arzneimittel Pütter GmbH & Co. KG
• MCM Klosterfrau Vertriebsgesellschaft mbH
What Are The Regional Insights Into The Acute Pharyngitis Market?
North America was the largest region in the acute pharyngitis market in 2024. The regions covered in the acute pharyngitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.